In the decade prior to establishing The Sage Group, Mr. Ramseier served as President and Chief Executive Officer of two biopharmaceutical companies, OncoTherapeutics of Cranbury, NJ (acquired by Biomira, Inc. in 1996) and Immunetech Pharmaceuticals, Inc., of San Diego. He played a key role in Immunetech's 1989 strategic redirection and acquisition of DURA Pharmaceuticals, Inc., for which the company was renamed in 1991.

DURA became one of the fastest growing specialty pharmaceutical companies in the world and established itself as an emerging leader in the allergy/respiratory diseases and acute care specialty markets. Mr. Ramseier was an active member of the DURA Board of Directors for 14 years. As the CEO during the transition of the company, Mr. Ramseier, recruited the core management team which led Dura from less than $5 million to over $300 million in revenues. Dura was acquired in 2000 by Elan Pharmaceuticals at a valuation of $1.8 billion.

Prior to entering the emerging company arena, Mr. Ramseier spent 9 years with Booz, Allen and Hamilton, a recognized international management consulting firm. During his last 5 years with the firm, he was a partner in the Healthcare Industries Practice providing strategic planning services to such diverse clients as Johnson & Johnson, Bayer, The National Wholesale Druggists Association and Blue Cross. His work with the National Wholesale Druggists Association produced a landmark study of the U.S. drug wholesaling industry, which had a significant impact on the strategic direction of many of the leading drug wholesalers in the U.S. in the 1980's and 1990's.

Earlier in his career, he was Director of Marketing, Gynecological Products, at G.D. Searle and a Product Manager at Pfizer Laboratories.

He received his M.B.A. (With Distinction) from the Amos Tuck School of Business Administration, Dartmouth College and his B.S. in Chemistry from Washington & Lee University

Mr. Ramseier is a member of the board of directors of the Biotechnology Council of New Jersey. Mr. Ramseier was the founding Vice Chairman of the BCNJ. During his career, he has served on the boards of seven emerging lifescience companies.